Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

T. Le, Dung; Won Kim, Tae; Van Cutsem, Eric; Geva, Ravit; Jäger, Dirk; Hara, Hiroki; Burge, Matthew; H. O’Neil, Bert; Kavan, Petr; Yoshino, Takayuki; Guimbaud, Rosine; Taniguchi, Hiroya; Élez, Elena; Al‐Batran, Salah‐Eddin; M. Boland, Patrick; S. Crocenzi, Todd; E. Atreya, Chloé; Cui, Yi; Dai, Tong; Marinello, Patricia; A. Díaz, Luis; André, Thierry

doi:10.1200/jco.19.02107

Public

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Published in Journal of Clinical Oncology • Nov 14, 2019

Authors:

Dung T. Le

Tae Won Kim

Eric Van Cutsem

Abstract

PURPOSE: KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC). METHODS: This phase II open-label study involved 128 centers worldwide. Eligible pat...

Subject

Medicine

Internal medicine

Pembrolizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!